1. Home
  2. GLMD vs DRMA Comparison

GLMD vs DRMA Comparison

Compare GLMD & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$0.57

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLMD
DRMA
Founded
2000
2014
Country
Israel
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
GLMD
DRMA
Price
$0.57
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
4.5M
64.6K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.59
52 Week High
$2.34
$7.33

Technical Indicators

Market Signals
Indicator
GLMD
DRMA
Relative Strength Index (RSI) 42.73 49.86
Support Level $0.50 $1.13
Resistance Level $0.69 $1.40
Average True Range (ATR) 0.04 0.09
MACD -0.01 0.01
Stochastic Oscillator 16.78 50.00

Price Performance

Historical Comparison
GLMD
DRMA

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: